Breaking Finance News

TheStreet downgraded Mylan NV (NASDAQ:MYL) to Hold in a report released today.

Yesterday Mylan NV (NASDAQ:MYL) traded -0.91% lower at $38.57. The company’s 50-day moving average is $42.90 and its 200-day moving average is $44.47. The last closing price is down -14.28% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 7,298,747 shares of the stock were exchanged, up from an average trading volume of 5,988,950

TheStreet has downgraded Mylan NV (NASDAQ:MYL) to Hold in a report released on 09/28/2016.

Previously on 9/06/2016, RBC Capital Markets reported on Mylan NV (NASDAQ:MYL) lowered the target price from $52.00 to $48.00. At the time, this indicated a possible upside of 0.20%.

See Chart Below


Mylan NV has a 52 week low of $37.59 and a 52 week high of $55.51 with a P/E ratio of 24.13 The company’s market cap is currently $0.

General Information About Mylan NV (NASDAQ:MYL)

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *